A special free project called the Laugh at Cancer Org. Encouragement Card Project is available to any cancer patient or survivor. Cards will be mailed out 1-2 times a month for the duration of either six months or a year, in order to cheer on the patient or survivor. We hope to provide encouragement, faith, hope, laughter, and support.
But, your help is needed to keep it up and running.
Here how you can help:
• Stamps
• Envelopes
• Greeting cards
• Card stock
• packing supplies
• Office supplies
• Gifts of Love or Donations
• Small gifts to enclose in cards
• Bookmarks
• Pocket cards
• Gift cards
The organization also runs a project titled “Pray for Me.” If you are struggling and in need prayer, join the Pray for Me Project. Volunteers will pray for you and your situation in private on a daily basis. You prayer is always kept confidential and will only be repeated to my prayer team.
To find out more, contact Laugh at Cancer at:
http://laughatcancer.com/wings_of_hope
Laugh at Cancer Organization Inc.
P.O. Box 7332
Jacksonville, FL 32238
United States
ph: (904) 415-6653
[email protected]
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...